ABSTRACT
Th1 cells preferentially express CXCR3, CCR5 and CCR6, while CCR3 and CCR4 are predominantly expressed by Th2 cell subsets. Multiple Sclerosis [MS] is a TH-1 cell-dependant chronic inflammatory disease of the central nervous system, and immunomudolatory cytokines could alter the chemokine expression pattern of these lymphocyte subsets. This study was performed to measure chemokine receptor expression on CD4 T cells for evaluation of Th1/ Th2 dominantly in IFN-beta treated patients. Flowcytometry was used to detect chemokine receptor expression on CD4 T cell population in PBMCs obtained from MS and healthy control groups. Twenty six MS patients participated in this study before and after IFN-beta therapy and the same number of healthy individuals were included. The percentage of lymphocytes was 41.28 +/- 10.30 in the blood of MS group compared with 36.88% +/- 5.51% in the control group [p=0.017]. The CD4[+] CXCR3[+] cells were 18.86% +/- 8.46% in healthy group, 30.78% +/- 9.8% in pre-treated MS patients and 21.06% +/- 9.23% in post-treated group [p<0.001]. The CD4[+]CCR4[+] cell subsets were 27.35% +/- 10.15% in healthy group; 28.17% +/- 8.9% in pre-treated group and 34.20% +/- 8.96% in the post-IFN-beta treatment group. The subset of CD4[+]CCR4[+] was found to be dominant after IFN-beta therapy in comparison with the control group [p<0.001]. CD4[+]CCR5[+] percentage was 1.24% +/- 0.92% in the healthy people, 1.23% =/- 0.71% in the MS patients and 0.76% +/- 0.49% in post-treatment status [p=0.003]. CD4[+]CCR3[+] cell subsets were 0.62% +/- 0.67% in control group, 0.28% +/- 0.26% in the MS patients [p=0.022] and 0.39% +/- 0.54% in IFN-beta treated patients [p=0.334]. An association was found for CXCR3 expression in pre- and post- treatment status [r=0.840, p<0.001] as well as for CCR4[+] expression [r=0.712, p<0.001] in the same groups. The Th1 response was dominant in pre-treatment states, and then the chemokine receptor expression of Th1/Th2 cell subsets could be used for monitoring and the evaluation of the MS disease status